FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology and medicine, particularly to methods of introducing autologous and/or allogenic B-cells genetically modified for production of a drug such as follistatin.
EFFECT: cells and methods of the present invention can be used for long-term delivery of follistatin in vivo.
81 cl, 5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, SUITABLE IN TREATMENT OF OSTEOARTHRITIS AND SIMILAR JOINT DISEASES IN MAMMALS | 2017 |
|
RU2771490C2 |
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2809246C2 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING MUCOLIPIDOSIS TYPE II | 2016 |
|
RU2742612C2 |
| METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS | 2019 |
|
RU2824194C2 |
| METHODS AND COMPOSITIONS FOR TRANSDUCTION AND EXPANSION OF LYMPHOCYTES AND REGULATION OF ACTIVITY THEREOF | 2018 |
|
RU2820974C1 |
| CHIMERIC ANTIGENIC RECEPTORS TO BCMA | 2015 |
|
RU2747457C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH CODES BLOOD COAGULATION FACTOR IX PROTEIN, AND USE THEREOF | 2021 |
|
RU2831751C2 |
